Hoffmann-La Roche: all 2,744 studies
Page 17 of 28. Open to participants first (117), then studies with results posted, then the rest; newest registration first within each.
- A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCLCompletedNCT03467373Phase 1
- Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid TumorsTerminatedNCT03454243Early Phase 1
- A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing CancersActive, not recruitingNCT03448042Phase 1
- Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia AActive, not recruitingNCT03432520
- A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)TerminatedNCT03399643
- A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Multiple Ascending Doses of GDC-0334 and the Effect of Food on the Pharmacokinetics of GDC-0334 in Healthy Adult ParticipantsTerminatedNCT03381144Phase 1
- Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic LeukemiaCompletedNCT03374137
- A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin LymphomaWithdrawnNCT03369964Phase 1
- A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid TumorsCompletedNCT03362723Phase 1
- A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy ParticipantsCompletedNCT03341884Phase 1
- Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI TherapyCompletedNCT03333655Phase 4
- A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast CancerActive, not recruitingNCT03332797Phase 1
- Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer PatientsCompletedNCT03330990Phase 1
- A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in ArgentinaCompletedNCT03330886
- A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in ArgentinaCompletedNCT03321695
- A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)CompletedNCT03301883Phase 4
- A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction ChemotherapyCompletedNCT03298516Phase 1
- Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)CompletedNCT03295877Phase 1
- A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular HypertensionCompletedNCT03293992Phase 1
- A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast CancerTerminatedNCT03292172Phase 1
- A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical PracticeCompletedNCT03291457
- A Study to Investigate the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics (PK) of GDC-0853 in Healthy ParticipantsCompletedNCT03290703Phase 1
- A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic TumorsCompletedNCT03289962Phase 1
- An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)CompletedNCT03289182
- Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)CompletedNCT03275103Phase 1
- A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell LymphomaCompletedNCT03274492Phase 3
- Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in KoreaCompletedNCT03271554
- A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-ThalassemiaCompletedNCT03271541Phase 2
- A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6CompletedNCT03255096Phase 1
- Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female ParticipantsCompletedNCT03237741Phase 1
- Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy ParticipantsCompletedNCT03236844Phase 1
- A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)CompletedNCT03232593
- A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on IpatasertibCompletedNCT03222310Phase 1
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7049665 in Healthy VolunteersCompletedNCT03221179Phase 1
- An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)CompletedNCT03202368Phase 3
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian ParticipantsCompletedNCT03188783Phase 1
- A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy ParticipantsCompletedNCT03182504Phase 1
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03178552Phase 2/3
- A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract InfectionCompletedNCT03174795Phase 1
- A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and SimvastatinCompletedNCT03174041Phase 1
- Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung CancerCompletedNCT03170284
- Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) AntibioticsCompletedNCT03162250Phase 1
- Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT03157635Phase 1/2
- An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) TherapyCompletedNCT03155347Phase 3
- A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung CancerCompletedNCT03155009Phase 2
- An Expanded Access Program of Emicizumab in Participants With Hemophilia A With InhibitorsApproved for marketingNCT03154437
- Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast CancerCompletedNCT03153163Phase 1
- A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)Active, not recruitingNCT03148418Phase 3
- A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])CompletedNCT03139513
- Quality of Life Study in Participants With IPF Under Pirfenidone TreatmentCompletedNCT03115619
- Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) TreatmentCompletedNCT03112213
- A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast CancerCompletedNCT03101280Phase 1
- Compare Bioavailability of RO7239361 After Subcutaneous InjectionCompletedNCT03100630Phase 1
- An Observational Study Evaluating the Productivity and Health-Related Quality of Life of People With HER2 Positive Breast CancerCompletedNCT03099200
- A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer SpecimensCompletedNCT03092739
- Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast CancerCompletedNCT03084939Phase 3
- A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's LymphomaActive, not recruitingNCT03075696Phase 1/2
- A Study to Evaluate Safety and Effectiveness of Bevacizumab in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Participants With Advanced Cervical CancerCompletedNCT03071848
- Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple MyelomaCompletedNCT03068351Phase 1
- Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene FusionsNo longer availableNCT03066661
- Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)CompletedNCT03063762Phase 1
- A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver DiseaseCompletedNCT03060538Phase 1
- Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in ArgentinaCompletedNCT03059251
- Expanded Access to RXDX-105 for Cancers With RET AlterationsNo longer availableNCT03052569
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) in Healthy Japanese ParticipantsCompletedNCT03040635Phase 1
- A Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Labeled Risdiplam (RO7034067) in Healthy Male ParticipantsCompletedNCT03036501Phase 1
- To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast CancerActive, not recruitingNCT03006172Phase 1
- A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)CompletedNCT02996019Phase 1
- Study to Compare the Pharmacokinetics of Mycophenolate Mofetil Metabolites From Four Tablet Formulations in Healthy ParticipantsCompletedNCT02981290Phase 1
- A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901CompletedNCT02975388Phase 1
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy VolunteersCompletedNCT02972255Phase 1
- A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on HemodialysisCompletedNCT02965053Phase 1
- Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi ArabiaCompletedNCT02954471
- Monitoring of Multiple Sclerosis (MS) Participants With the Use of Digital Technology (Smartphones and Smartwatches) - A Feasibility StudyCompletedNCT02952911Not applicable
- A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic StrokeTerminatedNCT02928393Phase 2
- A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and ComorbiditiesCompletedNCT02915224
- A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)CompletedNCT02913456
- A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)CompletedNCT02913443Phase 1
- A Non-Interventional Safety Study of Balsamic BactrimCompletedNCT02902640
- A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)CompletedNCT02892318Phase 1
- A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy ParticipantsCompletedNCT02882009Phase 1
- A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute BronchitisCompletedNCT02879981
- Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other TumorsCompletedNCT02876224Phase 1
- A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal ImpairmentCompletedNCT02864199Phase 4
- A Study to Assess the Relative Bioavailability And Food Effect of a Tablet Formulation of GDC-0276 in Healthy ParticipantsWithdrawnNCT02856152Phase 1
- APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and RibavirinCompletedNCT02850289
- To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast CancerCompletedNCT02846428Phase 2
- A Study of the Excretion Balance of Radiocarbon and the Pharmacokinetics and Metabolic Profile of TRO19622 (Olesoxime)CompletedNCT02835976Phase 1
- The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot UlcersCompletedNCT02833389Phase 1
- A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS StatusCompletedNCT02831842
- A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)CompletedNCT02828930Phase 1
- A Study of Epoetin Beta (NeoRecormon) in Anemic Participants With Diabetes and Chronic Renal Failure Who Are Not on DialysisCompletedNCT02827266Phase 3
- A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT02825940Phase 1
- A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With AntipsychoticsCompletedNCT02824055Phase 1
- A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's DiseaseCompletedNCT02820896Phase 1
- Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway InhibitorCompletedNCT02814669Phase 1
- A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing ChemotherapyCompletedNCT02813785Phase 3
- Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple SclerosisNo longer availableNCT02807285
- A Pharmacokinetic Study of [14C]-GDC-0810 After Single Oral Administration in Healthy Female ParticipantsCompletedNCT02802670Phase 1
- A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)CompletedNCT02797769